Source: Shutterstock ProQR (NASDAQ:PRQR) stock is rising on Thursday thanks to an expanded licensing and collaboration agreement with Eli Lilly (NYSE:LLY). Specifically, the agreement concerns ProQR’s Axiomer RNA-editing platform. The goal of developing this platform is for the treatment of both liver and nervous system disorders. ProQR notes that recent developments with Axiomer have “significantly…

Investing in biotech stocks is not everyone’s cup of tea. A lot of it is because of the volatility that comes with investing in them. The reason for the volatile swings in biotech stocks is that they tend to trade on catalysts. The outcomes of trial data, regulatory approvals, and other company data are crucial…